Efficacy, safety and tolerability of growth hormone in patients with amyotrophic lateral sclerosis as add-on therapy to riluzole.

Trial Profile

Efficacy, safety and tolerability of growth hormone in patients with amyotrophic lateral sclerosis as add-on therapy to riluzole.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2012

At a glance

  • Drugs Somatropin (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Apr 2011 Results presented at the 63rd Annual Meeting of the American Academy of Neurology.
    • 15 Apr 2011 Identifiers FARM53XBKT and RF-SDN2007-666932 added
    • 26 May 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top